---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-024042"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T14:09:55.138719+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# China NMPA approves Zai Lab's VYVGART for generalized myasthenia gravis

## Summary
- NMPA approved VYVGART (efgartigimod alfa) as add-on for anti-AChR+ gMG adults.
- Phase 3 ADAPT: 68% responders on MG-ADL vs 30% placebo (p<0.0001) in first cycle.
- Zai Lab to seek National Reimbursement Drug List inclusion for broader patient access.
- Zai Lab holds exclusive license from argenx to develop/commercialize in mainland China, HK, Macau, Taiwan.
- VYVGART is the first approved FcRn antagonist for gMG in China; ~200,000 MG patients in country.

## SEC filing metadata
- accession: 0001628280-23-024042
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828023024042/0001628280-23-024042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828023024042/zlab-20230630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-024042
- JSON: https://secwatch.observer/filing/0001628280-23-024042.json
- Plain text: https://secwatch.observer/filing/0001628280-23-024042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.